SEC Comment Letter for Vaxart, Inc. (VXRT) (CIK 0000072444) (VXRT) — Sep 18, 2019
Vaxart, Inc. (VXRT) (CIK 0000072444)
Date: Sept. 18, 2019 · CIK: 0000072444 · Accession: 0000000000-19-013724
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233717
Letter
September 18, 2019 Wouter Latour Chief Executive Officer Vaxart, Inc. 290 Utah Ave, Ste. 200 South San Francisco, CA 94080 Re:Vaxart, Inc. Registration Statement on Form S-1 Filed September 11, 2019 File No. 333-233717 Dear Dr. Latour: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tonya K. Aldave at (202) 551-3601 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: John T. McKenna, Esq.
Show Raw Text
September 18, 2019
Wouter Latour
Chief Executive Officer
Vaxart, Inc.
290 Utah Ave, Ste. 200
South San Francisco, CA 94080
Re:Vaxart, Inc.
Registration Statement on Form S-1
Filed September 11, 2019
File No. 333-233717
Dear Dr. Latour:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tonya K. Aldave at (202) 551-3601 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: John T. McKenna, Esq.